HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

TFC-612, a prostaglandin E1 derivative, enhances fibrinolytic activity in rats.

Abstract
TFC-612 inhibited thrombus formation on wire coils inserted into the lumen of the inferior vena cava of rats after 5 oral doses of 1.0 and 3.2 mg/kg and subcutaneous doses of 1.0 and 3.2 micrograms/rat/hr. This compound showed slight inhibition of platelet aggregation induced by collagen at 1.0 and 3.2 mg/kg (po) and significant inhibition at 10 mg/kg. TFC-612 had no effect on the plasma coagulation system at 3.2 mg/kg. Conversely, oral doses of 0.32-3.2 mg/kg dose- dependently enhanced fibrinolytic activity as measured by euglobulin clot lysis time and lysis area on fibrin plates by euglobulin fraction. TFC-612 did not enhance fibrinolytic activity in vitro. These results suggest that the enhancement of fibrinolytic activity by TFC-612, which may be due to an increase in tissue plasminogen activator release or reduction of plasminogen activator inhibitors release, contributes to its inhibition of thrombus formation.
AuthorsY Motoyama, Y Sakata, J Seki, M Sato, Y Namikawa, H Horiai, T Ono
JournalThrombosis research (Thromb Res) Vol. 65 Issue 1 Pg. 55-63 (Jan 01 1992) ISSN: 0049-3848 [Print] United States
PMID1604443 (Publication Type: Journal Article)
Chemical References
  • Fibrinolytic Agents
  • Platelet Aggregation Inhibitors
  • TFC 612
  • Alprostadil
Topics
  • Alprostadil (analogs & derivatives, pharmacology)
  • Animals
  • Blood Coagulation (drug effects)
  • Disease Models, Animal
  • Fibrinolytic Agents (pharmacology)
  • Male
  • Platelet Aggregation Inhibitors (pharmacology)
  • Rats
  • Rats, Inbred Strains
  • Thrombophlebitis (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: